ReviewiLIVER2022
Application of immune checkpoint inhibitors in hepatobiliary cancers.
Review in iLIVER, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and Validation of a Novel Nomogram Integrated with Hypoxic and Lactate Metabolic Characteristics for Prognosis Prediction in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatobiliary cancers are primarily categorized into hepatocellular carcinoma (HCC) and biliary tract cancers (BTC). HCC is one of the most common malignant cancers, with increasing global incidence. Immune checkpoint inhibitors (ICIs) have changed the approach of HCC management in recent years. The combination of atezolizumab and bevacizumab has surpassed sorafenib as the standard regimen for first-line treatment of advanced unresectable HCC. However, the optimal choice for second-line treatment after initial treatment with ICIs lacks clinical trial confirmation. In addition, limited clinical trial data on ICIs combined with locoregional and perioperative therapies have been reported. Unlike HCC, clinical studies have found that immunotherapy is effective only for BTC with specific molecular markers. Moreover, the molecular characteristics governing immune responses and evasion remain unclear. This review provides information on the application of immunotherapy for HCC and prospects over the next few years. In addition, current evidence from clinical trials of BTC has made BTC immunotherapy a research hotspot again. Based on the findings in the literature, future clinical trials are being planned. Furthermore, biomarkers used in immunotherapies for hepatobiliary cancers that may shed light on the management of these diseases in the future were discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.